Literature DB >> 12458671

Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration.

Jing Li1, Hung Huynh, Eli Chan.   

Abstract

PURPOSE: This study was undertaken to elucidate the underlying mechanism of the irregular absorption profiles of COL-3, a matrix metalloproteinase inhibitor, with a double- or plateau-peak concentration after a single oral dose administration of COL-3 suspension to rats.
METHODS: The gastrointestinal absorption profiles of COL-3 in rats were assessed by comparing serum drug concentration curves after the following various modes of drug administration: oral and intraduodenal doses, oral doses of COL-3 in fine and coarse suspensions, intraduodenal dosing to the bile-duct intact and cannulated (BDC) rats, and oral doses with and without food. In addition, the biliary excretion of COL-3 in the BDC rats was examined.
RESULTS: Neither variable gastric emptying nor enterohepatic recycling was the source of the irregular gastrointestinal absorption of COL-3 in rats. Reduction in particle size, presence of food and endogenous bile emerged as the determinants of the oral absorption of COL-3 by enhancing the dissolution of the solid drug in the gastrointestinal fluids. Flip-flop of the absorption and elimination rate constants was noted only for COL-3 after intraduodenal administration of the coarse suspension to the BDC rats with the bile flow diverged out of the body.
CONCLUSIONS: Variability in dissolution rate-limited absorption was the main cause of the irregular absorption of COL-3 after oral administration of its solid dosage form.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12458671     DOI: 10.1023/a:1020901328583

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  31 in total

1.  CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer.

Authors:  M G Selzer; B Zhu; N L Block; B L Lokeshwar
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

2.  Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption.

Authors:  S K Paulson; M B Vaughn; S M Jessen; Y Lawal; C J Gresk; B Yan; T J Maziasz; C S Cook; A Karim
Journal:  J Pharmacol Exp Ther       Date:  2001-05       Impact factor: 4.030

3.  Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.

Authors:  M A Rudek; W D Figg; V Dyer; W Dahut; M L Turner; S M Steinberg; D J Liewehr; D R Kohler; J M Pluda; E Reed
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

4.  The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon.

Authors:  R L Oberle; G L Amidon
Journal:  J Pharmacokinet Biopharm       Date:  1987-10

5.  Effect of bile salts on the gastrointestinal absorption of drugs. I.

Authors:  K Kakemi; H Sezaki; R Konishi; T Kimura; M Murakami
Journal:  Chem Pharm Bull (Tokyo)       Date:  1970-02       Impact factor: 1.645

6.  Influence of bile on the gastrointestinal absorption of phenytoin in rats.

Authors:  D Shinkuma; T Hamaguchi; Y Yamanaka; N Mizuno; N Yata
Journal:  Chem Pharm Bull (Tokyo)       Date:  1985-11       Impact factor: 1.645

7.  CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer.

Authors:  H M Lee; L M Golub; J Cao; O Teronen; M Laitinen; T Salo; S Zucker; T Sorsa
Journal:  Curr Med Chem       Date:  2001-02       Impact factor: 4.530

8.  Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles of cimetidine after oral administration in dogs.

Authors:  V Mummaneni; G L Amidon; J B Dressman
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

9.  Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.

Authors:  J Hasselström; J Säwe
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

10.  Regional gastrointestinal absorption of ranitidine in the rat.

Authors:  A B Suttle; K L Brouwer
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

View more
  5 in total

Review 1.  Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development.

Authors:  Jaime A Yáñez; Connie M Remsberg; Casey L Sayre; M Laird Forrest; Neal M Davies
Journal:  Ther Deliv       Date:  2011-05

2.  Alteration of the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, due to acute gastrointestinal toxicity of doxorubicin.

Authors:  Jing Li; Shufeng Zhou; Hung Huynh; Wei Duan; Eli Chan
Journal:  Pharm Res       Date:  2005-08-13       Impact factor: 4.200

3.  Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline.

Authors:  Jing Li; Shufeng Zhou; Hung Huynh; Eli Chan
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

4.  Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas.

Authors:  Michelle A Rudek; Pamela New; Tom Mikkelsen; Surasak Phuphanich; Jane B Alavi; Louis B Nabors; Steven Piantadosi; Joy D Fisher; Stuart A Grossman
Journal:  J Neurooncol       Date:  2011-05-06       Impact factor: 4.130

5.  A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas.

Authors:  Quincy S C Chu; Bahram Forouzesh; Samira Syed; Monica Mita; Garry Schwartz; Joshua Cooper; Joshua Copper; Janet Curtright; Eric K Rowinsky
Journal:  Invest New Drugs       Date:  2007-01-20       Impact factor: 3.651

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.